The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml

European Urology

Volumn 42, Issue 4, 2002, Pages 333-337

  Morote, Juan ^a   Trilla, Enrique ^a   Esquena, Salvador ^a   Serrallach, Francesccedil ^a   Abascal, Joseacute Ma ^a   Muoz, Aurelio ^a   Id M'Hammed, Youssef ^a   De Torres, Ineacutes M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Percentage of free PSA; Prostate cancer diagnosis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CLUSTER ANALYSIS; HUMAN; MALE; PALPATION; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; ROC CURVE; ADULT; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; DIAGNOSTIC ACCURACY; DISEASE MARKER; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; CLUSTER ANALYSIS; HUMANS; MALE; PALPATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036793867     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00318-4     Document Type: Article

References (15)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostatic-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-90.
2. Cooner WH, Mosley BR, Rutherford CL, Beard JJ, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. J Urol 1990;143:1146-52.
3. Christensson A, Bjork T, Nilsson O, Bahlen U, Matikainen MT, Cockett AJK, et al. Serum prostate-specific antigen complexed to α-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
4. Morote J, Raventós CX, Lorente JA, López-Pacios MA, Encabo G, de Torres I, Andreu J. Comparison of percent free prostatic-specific antigen and prostate-specific antigen density as methods to enhance prostate-specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate-specific antigen between 4.1 and 10 ng/ml. J Urol 1997;158:502-6.
5. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
6. Catalona WJ, Smith DS, Ornstein KK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4 ng/ml and benign prostate examination. JAMA 1997;277:1452-5.
7. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
8. Woodrum DL, French CF, Shamel LB. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions. Urology 1997;48(Suppl):33-9.
9. Woodrum DL, French CF, Hill TM, Romai SJ, Slatore HC, Shaffer JL, et al. Analytical performance of the Tandem-R free PSA immunoassay measuring free prostatic-specific antigen. Clin Chem 1997;43:1203-8.
10. SPSS for Windows. Base System User's Guide Release 6.0. Chicago: SPSS Inc., 1993.
11. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan PW. Analysis of percent free prostate-specific antigen for prostate cancer detection: influence of total serum PSA, prostate volume, and age. Urology 1996;48(Suppl):55-60.
12. Littrup PJ, Goodman AC. Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction. Cancer 1995;75(Suppl):1987-93.
13. Hofer C, Sauerstein P, Wolter C, Scholz M, Hartung R, Breul J. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist. Urol Int 2000;64:18-23.
14. Martinez-Piñeiro L, Tabernero A, Contreras A, Madero R, Lozano D, López-Tello J, et al. Determination of the percentage of free prostatic-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostatic-specific antigen of 4-10 ng/ml. Eur Urol 2000;37:289-96.
15. Vessella R, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, et al. Probability of prostate cancer detection bases on results of a multicenter study using the AxSYM free PSA and PSA assays. Urology 2000;55:909-14.